Social Capital Annual Letter
- “The real expense in a startup shouldn’t be their bill from Big Tech (e.g., ad spend on Google/FB/Amazon) but, rather, the cost of real innovation and R&D.” The second is to break away from the multilevel marketing scheme that the VC-LP-user growth game has become.”
Carlos Ghosn 2010 Talk at Stanford GSB
- “What is management about? Asking people to do things they don’t want to do.”
- “It’s better to be two mules than two horses in the car industry: more resistant to the shocks.”
- “There are some basic conditions, and if you don’t see them, forget about leadership… If somebody doesn’t listen, no way… The test is, start a boring conversation with them. Obviously, if you’re very interesting, it’s easy to listen. No, you go for a boring conversation. If you’re a leader, you’re a listener… The second thing, I’ve never seen a boring leader. A leader is always someone interesting, someone who can connect with you.”
- “Don’t work for recognition. It’s an illusion. Somebody once said, ‘if you want recognition, by yourself a dog.'”
Carlos Ghosn on Globalization (French interview)
- “Mondialization c’est deux choses qui vient tout de suite a l’esprit: ouvertures et exigences. Ouverture c’est evident: sur les marches, les cultures, les opportunites. Mais des que vous parlez des ouvertures, vous parlez de competition, de concurrences.”
- “Vous ne pouvez plus produir loin de vos marches. Aujourd’hui 96% des voitures vendus en Chine sont produit en Chine.”
Andreessen Horowitz on the Looming Shortage of Physicians
- A shortage of physicians in the coming decade, as reported by the Association of American Medical Colleges, will likely reduce the prevalence of physicians both capable of navigating the complex medical landscape as well as ready to take up innovative solutions and work with biomedical startups. This includes providing startups with feedback to the following questions:
- What are the logistical challenges of how health care is delivered? What are the financial incentives for providers?
- Who “controls” access to patients — and their lab samples — for clinical studies and for patient care?
- How do we align the interests of providers and patients, so these innovations make sense for both?